Agreement to Expand Distribution for MR Volumetric Brain Atrophy Software
By MedImaging International staff writers Posted on 10 Feb 2014 |
New software is the only US Food and Drug Administration (FDA)-approved medical device capable of automatically detecting and quantifying atrophy in the human brain and provides accurate, and fully automated magnetic resonance imaging (MRI) post-processing capabilities to the physician’s mobile device or desktop.
This provides radiologists, neuroadiologists, and clinical researchers with a convenient and cost-effective way to quantify atrophy of brain structures to help identify a range of brain disorders, including conditions such as Alzheimer’s disease, epilepsy and traumatic brain injury.
CorTechs Labs (La Jolla, CA, USA) reported that it is renewing and expanding a partnership and distribution agreement with Invivo Corp. (Gainesville, FL, USA; a subsidiary of Philips Healthcare [Best, The Netherlands]) for NeuroQuant, a software solution for volumetric brain atrophy in the US healthcare market.
NeuroQuant is a crucial part of Invivo’s DynaSuite neuroimaging solution. “We’re pleased to expand our relationship with Invivo. With great expertise and presence in advanced clinical solutions for MRI, Invivo has been a terrific partner and has demonstrated exceptional growth with our NeuroQuant product in the US,” said Guri Stark, CorTechs Labs’ CEO. “We look forward to partnering with Invivo to continue NeuroQuant’s growth momentum and establishing our vision to have NeuroQuant become the standard test for all brain disorders, including Alzheimer’s disease, epilepsy and traumatic brain injury.”
“CorTechs Labs is a pioneer in the area of software for the aid of brain diagnostics and has a tremendous track record of reliability and automation in clinical practices,” stated Tom Tynes, director of strategic business development at Invivo. “We look forward to continuing to offer our DynaSuite neuroimaging solution with NeuroQuant, benefitting from its innovative approach to providing the much needed quantitative brain volumetric information.”
CorTechs Labs develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ cornerstone product, NeuroQuant, is a breakthrough, 510(k)-cleared medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice.
Invivo is a subsidiary of Philips Healthcare (Best, The Netherlands) and develops progressive MRI coils, cutting-edge clinical solutions, and MRI-compatible interventional devices.
Related Links:
CorTechs Labs
Invivo
This provides radiologists, neuroadiologists, and clinical researchers with a convenient and cost-effective way to quantify atrophy of brain structures to help identify a range of brain disorders, including conditions such as Alzheimer’s disease, epilepsy and traumatic brain injury.
CorTechs Labs (La Jolla, CA, USA) reported that it is renewing and expanding a partnership and distribution agreement with Invivo Corp. (Gainesville, FL, USA; a subsidiary of Philips Healthcare [Best, The Netherlands]) for NeuroQuant, a software solution for volumetric brain atrophy in the US healthcare market.
NeuroQuant is a crucial part of Invivo’s DynaSuite neuroimaging solution. “We’re pleased to expand our relationship with Invivo. With great expertise and presence in advanced clinical solutions for MRI, Invivo has been a terrific partner and has demonstrated exceptional growth with our NeuroQuant product in the US,” said Guri Stark, CorTechs Labs’ CEO. “We look forward to partnering with Invivo to continue NeuroQuant’s growth momentum and establishing our vision to have NeuroQuant become the standard test for all brain disorders, including Alzheimer’s disease, epilepsy and traumatic brain injury.”
“CorTechs Labs is a pioneer in the area of software for the aid of brain diagnostics and has a tremendous track record of reliability and automation in clinical practices,” stated Tom Tynes, director of strategic business development at Invivo. “We look forward to continuing to offer our DynaSuite neuroimaging solution with NeuroQuant, benefitting from its innovative approach to providing the much needed quantitative brain volumetric information.”
CorTechs Labs develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ cornerstone product, NeuroQuant, is a breakthrough, 510(k)-cleared medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice.
Invivo is a subsidiary of Philips Healthcare (Best, The Netherlands) and develops progressive MRI coils, cutting-edge clinical solutions, and MRI-compatible interventional devices.
Related Links:
CorTechs Labs
Invivo
Latest MRI News
- Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
- World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer